comprehensive -WSS

comprehensive

author：focus 2025-09-27 18:29:26 - browse：385

Most everything is looking up for Orexo, the company reported on its second quarter earnings call on Tuesday. That is, everything but its digital therapies pipeline.

The Swedish pharmaceutical company, which makes almost all of its money from U.S. sales of its drug for opioid dependence, notched a number of important victories in the quarter: It successfully defended its patents in a case against Sun Pharmaceuticals, it resolved a packaging issue that was holding up the approval of its long-acting rescue medication, and it grew revenues for Zubsolv, its most important product. The company trimmed its losses to 12.6 million SEK, or $1.2 million, and executives reported that with fewer one-time expenses on the horizon, profitability was “in sight.”

“We are at an exciting turning point for the company and I hope our self confidence and optimism is something that you can share,” CEO Nikolaj Sørensen said on the company’s earnings call while cautioning that “there’s a lot more work to be done.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Covid vaccine financial winners and losers, from Pfizer to Novavax

leisure time

WSS

Oprah kicked off a national conversation on obesity. Let's have it

Patient advocates debate FDA's accelerated approval process

Decaf coffee targeted by food safety group under obscure FDA rule

What to expect as Trump is arraigned on his Jan 6. indictment

There's no autism epidemic. It's an autism diagnosis epidemic

Washington mulls new rules to avert another Change Healthcare

leisure time

comprehensive

leisure time

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Listen: Biogen's situation, Wegovy's risks, & biotech insider trading

New air purifier tech could be key to improving indoor air quality

Pence says 'crackpot lawyers' told Trump what he wanted to hear

Jerome Adams on the need for new antivirals for Covid

Readout LOUD podcast: mifepristone case, GLP

Medicare proposal to cover medical devices draws a mixed reaction

There's no autism epidemic. It's an autism diagnosis epidemic

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Readout LOUD podcast: mifepristone case, GLP

focus

Scientists boost immune system in aging mice by making it youthful

Readout Newsletter: Merck, Vertex, and Viking updates

Mitch McConnell episode has important public health takeaway

Merck drug for rare lung condition set for approval in U.S.

What the US credit downgrade means for the economy, your finances

The high personal cost of affirmative action for Black doctors

leisure time

hotspot

focus

Wikipedia